CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life
science partner for data-driven answers in rare and
neurodegenerative diseases, today announced the voting results of
the Company’s Annual General Meeting. Shareholders voted in favor
of all proposals, which included the appointment of Prof. Dr. Peter
Bauer as a member of the Management Board of the Company, as well
as the appointment of Mary Sheahan and the reappointment of Peer
Schatz as members of the Supervisory Board of the Company.
The shareholders extended the period for drawing
up the Dutch statutory annual accounts and board report for the
financial year ended December 31, 2022. The shareholders also
approved the instruction to Ernst & Young Accountants LLP for
the external audit of the Company's annual accounts for the
financial year ended December 31, 2022, and the financial year
ending December 31, 2023. In addition, the shareholders extended
the authorization for the Company’s Management Board to issue
shares and grant rights to subscribe for shares, limit and exclude
pre-emption rights, and acquire shares and depository receipts for
shares in the Company's capital.
Peer Schatz, Chairman of the Supervisory Board
at CENTOGENE, said, “We would like to thank our shareholders for
their continued support of the Company’s mission. CENTOGENE has
recently made significant steps forward in our mission to deliver
data-driven, life-changing answers to patients around the world and
towards creating a pathway to achieving sustainable growth and
profitability.”
About CENTOGENE
CENTOGENE’s mission is to provide data-driven,
life-changing answers to patients, physicians, and pharma companies
for rare and neurodegenerative diseases. We integrate multiomic
technologies with the CENTOGENE Biodatabank – providing dimensional
analysis to guide the next generation of precision medicine. Our
unique approach enables rapid and reliable diagnosis for patients,
supports a more precise physician understanding of disease states,
and accelerates and de-risks targeted pharma drug discovery,
development, and commercialization.
Since our founding in 2006, CENTOGENE has been
offering rapid and reliable diagnosis – building a network of
approximately 30,000 active physicians. Our ISO, CAP, and CLIA
certified multiomic reference laboratories in Germany utilize
Phenomic, Genomic, Transcriptomic, Epigenomic, Proteomic, and
Metabolomic datasets. This data is captured in our CENTOGENE
Biodatabank, with over 750,000 patients represented from over 120
highly diverse countries, over 70% of whom are of non-European
descent. To date, the CENTOGENE Biodatabank has contributed to
generating novel insights for more than 275 peer- reviewed
publications.
By translating our data and expertise into
tangible insights, we have supported over 50 collaborations with
pharma partners. Together, we accelerate and de-risk drug
discovery, development, and commercialization in target & drug
screening, clinical development, market access and expansion, as
well as offering CENTOGENE Biodata Licenses and Insight Reports to
enable a world healed of all rare and neurodegenerative
diseases.
To discover more about our products, pipeline,
and patient-driven purpose, visit www.centogene.com and follow us
on LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of the U.S. federal securities laws.
Statements contained herein that are not clearly historical in
nature are forward-looking, and the words “anticipate,” “believe,”
“continues,” “expect,” “estimate,” “intend,” “project,” “plan,” “is
designed to,” “potential,” “predict,” “objective” and similar
expressions and future or conditional verbs such as “will,”
“would,” “should,” “could,” “might,” “can,” and “may,” or the
negative of these are generally intended to identify
forward-looking statements. Such forward-looking statements involve
known and unknown risks, uncertainties, and other important factors
that may cause CENTOGENE’s actual results, performance, or
achievements to be materially different from any future results,
performance, or achievements expressed or implied by the forward-
looking statements. Such risks and uncertainties include, among
others, negative economic and geopolitical conditions and
instability and volatility in the worldwide financial markets,
possible changes in current and proposed legislation, regulations
and governmental policies, pressures from increasing competition
and consolidation in our industry, the expense and uncertainty of
regulatory approval, including from the U.S. Food and Drug
Administration, our reliance on third parties and collaboration
partners, including our ability to manage growth, execute our
business strategy and enter into new client relationships, our
dependency on the rare disease industry, our ability to manage
international expansion, our reliance on key personnel, our
reliance on intellectual property protection, fluctuations of our
operating results due to the effect of exchange rates, our ability
to streamline cash usage, our continued ongoing compliance with
covenants linked to financial instruments, our requirement for
additional financing and our ability to continue as a going
concern, or other factors. For further information on the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to CENTOGENE’s business in general, see CENTOGENE’s risk
factors set forth in CENTOGENE’s Form 20-F filed on May 16, 2023,
with the Securities and Exchange Commission (the “SEC”) and
subsequent filings with the SEC. Any forward- looking statements
contained in this press release speak only as of the date hereof,
and CENTOGENE’s specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
CONTACT
Melissa HallCorporate Communications
Press@centogene.com
Lennart StreibelInvestor Relations
IR@centogene.com
Centogene NV (NASDAQ:CNTG)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Centogene NV (NASDAQ:CNTG)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024